HUMAN MONOCLONAL ANTI-RHO-D IG

HUMAN MONOCLONAL ANTI-RHO-D IG: Drug: Human Monoclonal Anti-Rho(D) Ig

Use: Human Monoclonal Anti-Rho(D) Ig, also known as Rh immune globulin (RhIg), is primarily used to prevent the development of hemolytic disease of the newborn (HDN) in Rh(D) negative pregnant women who are at risk of producing anti-D antibodies. HDN can occur when an Rh(D) negative mother becomes sensitized to the Rh(D) antigen on the red blood cells of her Rh(D) positive fetus. RhIg works by preventing the production of these antibodies, reducing the risk of HDN in subsequent pregnancies.

Mechanism of Action: Human Monoclonal Anti-Rho(D) Ig works by binding to and suppressing the Rh(D) antigen on the surface of fetal red blood cells in the mother’s bloodstream. This prevents the mother’s immune system from recognizing the antigen and producing anti-D antibodies that could cause HDN in future pregnancies. RhIg does not have any direct effect on the fetus.

Dose: The dose of Human Monoclonal Anti-Rho(D) Ig is based on the mother’s Rh(D) negative status and the potential for fetal-maternal hemorrhage. It is usually administered as an injection, either intramuscularly or intravenously. The typical dose for RhIg is 300 µg (1500 IU). The timing of administration will depend on the specific circumstance, with doses given during and after pregnancy, as well as following invasive procedures or accidental exposure to Rh(D) positive blood.

Side Effects: Human Monoclonal Anti-Rho(D) Ig is generally considered safe and well-tolerated. However, like any medication, there can be potential side effects. Common side effects may include pain, redness, or swelling at the injection site. Rarely, allergic reactions may occur, manifesting as fever, rash, hives, or difficulty breathing. In very rare cases, severe allergic reactions, such as anaphylaxis, may occur. It is important to notify healthcare providers if any adverse effects are experienced after receiving RhIg.